An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers

5-Fluorouracil (5-FU) or a 5-FU derivative 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) has been widely prescribed for patients with gastrointestinal cancer. However, the phosphorylation of 5-FU in the digestive tract causes gastrointestinal toxicities. 5-FU is also rapidly degraded to α-fluoro-β-alanine after contact with dihydropyrimidine dehydrogenase (DPDase) which is mainly present in the liver. Therefore, to overcome these metabolic events, S-1, an antitumor agent was developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1. The antineoplastic effect of S-1, was examined in Japanese patients with advanced gastric (G) or colorectal (C) cancer in a multicenter early phase II study involving 24 centers throughout Japan. The patients were prescribed a minimum of 2 courses of S-1 orally, with each course consisting of 75 or 50 mg (in terms of FT) twice a day for 28 days followed by withdrawal for 2 weeks. Thirty-one patients with G and 31 C were entered into this study. The clinical response and extent of toxicity were evaluated in G 28 and C 30 cases, respectively. Nine (32.1%) G patients and 14 (46.7%) C patients had been treated previously with other anticancer drugs. In G patients, there was a 53.6% (15/28) and in C patients a 16.7% (5/30) response rate (90% confidence interval G 38.4–68.1% and C 8.4–30.5%) with 15 (53.6%) (G) and 5 (16.7%) (C) partial responses (PR), and these responses persisted for 79 days (G) and 120 days (C) (median value). In particular, the response rate for the primary lesion was 27.8% (5/18) (G) and 33.3% (1/3) (C). No change (NC) in the disease was observed in 4 (14.3%) (G) and 13 (43.3%) (C) patients, and in 6 (21.4%) (G) and 7 (23.3%) (C) the disease progressed (PD). At the time of analysis, the median survival was 298 days (G) and 358 days (C). Major adverse effects consisted of gastrointestinal symptoms and myelosuppression while toxicities of grade 3 or more occurred in 35.7% (10/28) (G) and 33.3% (10/30) (C). Based on these data, S-1 is considered to have positive effects in patients with advanced gastrointestinal cancer.

[1]  M. Buyse,et al.  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Maehara,et al.  Recurrences and related characteristics of gastric cancer. , 1996, British Journal of Cancer.

[3]  J. Verweij,et al.  Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[5]  A. Fujioka,et al.  Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. , 1996, Cancer research.

[6]  I. Seymour,et al.  ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Colucci Phase II study of 5‐fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: A Southwest Oncology Group study , 1996, Cancer.

[8]  O. Dassonville,et al.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Fleming,et al.  Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[11]  J. Wanders,et al.  Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. , 1994, British Journal of Cancer.

[12]  T. Taguchi,et al.  [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[13]  J. Ajani,et al.  Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Wieand,et al.  Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Fukushima,et al.  Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. , 1993, Cancer research.

[16]  T. Taguchi,et al.  Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Maehara,et al.  Cisplatin plus continuous infusion of 5‐fluorouracil for 5 days effective for patients with advanced gastric cancer , 1991, Anti-cancer drugs.

[18]  K. Sugimachi,et al.  [Phase II study of (2" R)-4'-O-tetrahydropyranyladriamycin (THP) in patients with advanced or recurrent gastric cancer. Clinical study group of THP for gastric cancer in Japan]. , 1991, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Arbuck,et al.  Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer , 1989, Cancer.

[21]  R. Pazdur,et al.  Low‐dose continuous infusion 5‐fluorouracil. Evaluation in advanced breast carcinoma , 1989, Cancer.

[22]  R. Ausman,et al.  Continuous 5‐Fluorouracil Infusion in Advanced Gastric Carcinoma , 1988, American journal of clinical oncology.

[23]  D. Haller Chemotherapy in gastrointestinal malignancies. , 1988, Seminars in oncology.

[24]  M. Fukushima,et al.  Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. , 1987, Japanese journal of cancer research : Gann.

[25]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[26]  O. Dalesio,et al.  cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. , 1985, European journal of cancer & clinical oncology.

[27]  S. Cha,et al.  Structure-activity relationship of pyrimidine base analogs as ligands of orotate phosphoribosyltransferase. , 1984, Biochemical pharmacology.

[28]  T. Rich,et al.  Patterns of recurrence of rectal cancer after potentially curative surgery , 1983, Cancer.

[29]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[30]  Y. Maehara,et al.  Metabolism of 5-fluorouracil in various human normal and tumor tissues. , 1981, Gan.

[31]  R. Wilson,et al.  Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum , 1980, Cancer.

[32]  P. Houghton,et al.  Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. , 1979, Cancer research.

[33]  K. Ikenaka,et al.  Effect of uracil on metabolism of 5-fluorouracil in vitro. , 1979, Gan.

[34]  藤井 節郎 Effect of Coadministration of Uracil or Cytosine on the Antitumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents , 1979 .

[35]  M. Fukushima,et al.  Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. , 1978, Gan.

[36]  S. Carter,et al.  A review of chemotherapy in gastric cancer , 1974, Cancer.

[37]  S. Kaufman 5-Fluorouracil in the treatment of gastrointestinal neoplasia. , 1973, The New England journal of medicine.

[38]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. D. De Braud,et al.  Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. , 1995, Oncology.

[40]  N. Kemeny,et al.  Recent advances in the treatment of advanced colorectal cancer , 1993, Cancer.

[41]  R. Fitzgibbons,et al.  Patterns of recurrence after curative resection of carcinoma of the colon and rectum. , 1992, Surgery, gynecology & obstetrics.